Investors

Share Information

Number of shares:  62,786,630

Total number of outstanding warrants: 938,164 (see below for details)

Warrant

Exercise price/share

Maximum amount of warrants

Expiry date

CBF1

EUR 4.94

12,629 shares

August 18, 2020

CBF2

EUR 2.90

21,513 shares

September 22, 2020

CBF3

EUR 1.95

34,231 shares

October 20, 2020

CBF4

EUR 1.76

74,384 shares

November 8, 2020

CBF5

EUR 1.68

148,769 shares

November 16, 2020

CBF6

EUR 1.60

334,462 shares

December 5, 2020

SEDA6

EUR 3.80

195,851 shares

March 8, 2020

SITRA3

EUR 3.80

41,122 shares

March 14, 2020

SITRA4

EUR 3.80

17,211 shares

June 6, 2020

KREOS

EUR 1.60

57,992 shares

July 13, 2022

 


Stock option plans total: 330,040 (see below for details)

Option scheme

Subscription price/share

Maximum amount of option rights

Subscription period

2013A

EUR 0.30

1,721 shares

 1.12.2013-31.12.2020

2016B

EUR 0.92

94,191 shares

 1.7.2019-15.12.2024

2016C

EUR 1.16

121,513 shares

1.7.2020-15.12.2025**

2017

EUR 0.92

39,285 shares

 20.10.2018-31.3.2023

2018A

EUR 0.26

36,665 shares

1.7.2022-15.12.2027

2018B

***

36,665 shares

1.7.2023-15.12.2028

** 67,048 stock options of the stock options 2016C have been amended in such way that the first possible share subscription date is July 1, 2021.

*** The share subscription price for stock options 2018B is the trade volume weighted average quotation of the share on Nasdaq Helsinki Ltd during twenty (20) trading days following the release date of the company’s Financial Statements of the year 2019.

Board of Directors authorizations outstanding total: 8,813,282 shares (see below an extract from the EGM 2019 decisions)

AUTHORIZING THE BOARD OF DIRECTORS TO DECIDE ON THE ISSUANCE OF SHARES AS WELL AS THE ISSUANCE OF OPTION RIGHTS AND OTHER SPECIAL RIGHTS ENTITLING TO SHARES

In accordance with the proposal of the Board of Directors, the 11 November 2019 Extraordinary General Meeting of Shareholders resolved to authorize the Board of Directors to decide on issuances of new shares either against payment or without consideration as follows:

The authorization would be given to a maximum quantity of 10,000,000 new shares.
The new shares may be issued to the Company's shareholders in proportion to their current shareholdings in the Company or deviating from the shareholders' pre-emptive right through one or more directed share issue, if the Company has a weighty financial reason to do so, such as developing the Company's equity structure, minimize or reduce debts, implementing mergers and acquisitions or other restructuring measures aimed at developing the Company's business, financing of investments and operations or using the shares as a part of the Company's remuneration and compensation system. The Board of Directors shall decide upon terms and scope related to share issues.

Based and within the limits of this authorization, the Board of Directors can also decide on issuance(s) of option rights or other special rights set forth in Chapter 10 Section 1 of the Limited Liability Companies Act complementing or replacing issuance(s) of shares.

The subscription price of the new shares can be recorded partly or fully to the invested unrestricted equity reserve or to share capital according to the decision of the Board of Directors.

The Board of Directors is entitled to decide on conditions regarding the issuance of shares as well as the issuance of option rights or other special rights entitling to shares.

The authorization is be valid for one year from the Extraordinary General Meeting.

All above share information last updated at 13 January 2020.

Terms and conditions for the stock options